Non arteritic ischemic optic neuropathy in a patient taking semaglutide: Is there a relation? A case report and a review of the literature

Introduction The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Semaglutide, have revolutionized the treatment of type 2 diabetes mellitus and obesity. Case desciption The aim of the present study was to report a case of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) occurring in a diabetic patient taking Semaglutide and to review the literature in order to find a possible relation between the ophthalmological event and the drug intake. Discussion Although the clinical trials of Semaglutide did not report any significant increase in the risk of NAION, a recent retrospective cohort study suggested a possible association between NAION and GLP-1 RAs. After this publication, the association between NAION and Semaglutide became an hot topic and several studies were published, presenting conflicting results. Conclusion and Importance Albeit the association between the use of GLP-1 RAs and NAION, to date, remain controversial, clinicians and ophthalmologists should be aware of such possible association to analyze for each patient the risk-benefit ratio.